Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis
Introduction Ziprasidone is an atypical antipsychotic that has demonstrated efficacy for the treatment of bipolar disorder and schizophrenia. There is some preliminary evidence for Ziprasidone use in children and adolescents with several open label studies and some randomized control trials, theref...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822010768/type/journal_article |
| _version_ | 1797617024065601536 |
|---|---|
| author | A. Wadhwa A. Sareen C. Soeung I. Penuelas-Calvo |
| author_facet | A. Wadhwa A. Sareen C. Soeung I. Penuelas-Calvo |
| author_sort | A. Wadhwa |
| collection | DOAJ |
| description |
Introduction
Ziprasidone is an atypical antipsychotic that has demonstrated efficacy for the treatment of bipolar disorder and schizophrenia. There is some preliminary evidence for Ziprasidone use in children and adolescents with several open label studies and some randomized control trials, therefore it is advantageous to understand where Ziprasidone lies in the treatment algorithm of children and adolescents.
Objectives
The aim of our study is to examine the efficacy and tolerability of Ziprasidone in children and adolescents.
Methods
We conducted a literature search consisting of open label or randomized control trials (RCT) that report on Ziprasidone use in children on the PubMed database. We found 13 studies (11 open label and 2 RCT) that met our inclusion criteria. Our outcome measures included efficacy measures such as BPRS, YMRS, CGI-S and adverse effects such as weight gain, increase in BMI, QTc prolongation, sedation, dizziness and EPS.
Results
Data from thirteen studies was meta-analyzed (Total n= 560, mean age=13.16 years, male= 70.35% that reported the use of Ziprasidone in children and adolescents. We found that Ziprasidone was efficacious in children and adolescents in measures of BPRS (-13.493, p<0.05), YMRS (-14.225, p<0.05), CGI-S (-1.430, p<0.05). In measures of adverse effects, Ziprasidone was not found to cause any significant weight gain (0.164, p>0.05) or change in BMI (-0.159, p>0.05). QTc prolongation was found to be significant (13.122, p<0.05).
Conclusions
Ziprasidone is an efficacious in children and adolescent population. It does not cause significant weight gain, however QTc prolongation and sedation were found to be the most significant side effects .
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:49:38Z |
| format | Article |
| id | doaj.art-c390ca271a664709bed79f45a37229d9 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:49:38Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-c390ca271a664709bed79f45a37229d92023-11-17T05:06:58ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S424S42410.1192/j.eurpsy.2022.1076Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta AnalysisA. Wadhwa0A. Sareen1C. Soeung2I. Penuelas-Calvo3University of Alabama, Psychiatry, Birmingham, United States of AmericaBronx Care Health System-Affiliated with the Icahn School of Medicine at Mount Sinai, Psychiatry, New York, United States of AmericaBronx Care health System, Psychiatry, New York, United States of AmericaFundación Jiménez Díaz, Psychiatry, Madrid, Spain Introduction Ziprasidone is an atypical antipsychotic that has demonstrated efficacy for the treatment of bipolar disorder and schizophrenia. There is some preliminary evidence for Ziprasidone use in children and adolescents with several open label studies and some randomized control trials, therefore it is advantageous to understand where Ziprasidone lies in the treatment algorithm of children and adolescents. Objectives The aim of our study is to examine the efficacy and tolerability of Ziprasidone in children and adolescents. Methods We conducted a literature search consisting of open label or randomized control trials (RCT) that report on Ziprasidone use in children on the PubMed database. We found 13 studies (11 open label and 2 RCT) that met our inclusion criteria. Our outcome measures included efficacy measures such as BPRS, YMRS, CGI-S and adverse effects such as weight gain, increase in BMI, QTc prolongation, sedation, dizziness and EPS. Results Data from thirteen studies was meta-analyzed (Total n= 560, mean age=13.16 years, male= 70.35% that reported the use of Ziprasidone in children and adolescents. We found that Ziprasidone was efficacious in children and adolescents in measures of BPRS (-13.493, p<0.05), YMRS (-14.225, p<0.05), CGI-S (-1.430, p<0.05). In measures of adverse effects, Ziprasidone was not found to cause any significant weight gain (0.164, p>0.05) or change in BMI (-0.159, p>0.05). QTc prolongation was found to be significant (13.122, p<0.05). Conclusions Ziprasidone is an efficacious in children and adolescent population. It does not cause significant weight gain, however QTc prolongation and sedation were found to be the most significant side effects . Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822010768/type/journal_articleZiprasidone |
| spellingShingle | A. Wadhwa A. Sareen C. Soeung I. Penuelas-Calvo Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis European Psychiatry Ziprasidone |
| title | Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis |
| title_full | Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis |
| title_fullStr | Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis |
| title_full_unstemmed | Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis |
| title_short | Efficacy and Tolerability of Ziprasidone Use in Children and Adolescents, a Systemic Review and Meta Analysis |
| title_sort | efficacy and tolerability of ziprasidone use in children and adolescents a systemic review and meta analysis |
| topic | Ziprasidone |
| url | https://www.cambridge.org/core/product/identifier/S0924933822010768/type/journal_article |
| work_keys_str_mv | AT awadhwa efficacyandtolerabilityofziprasidoneuseinchildrenandadolescentsasystemicreviewandmetaanalysis AT asareen efficacyandtolerabilityofziprasidoneuseinchildrenandadolescentsasystemicreviewandmetaanalysis AT csoeung efficacyandtolerabilityofziprasidoneuseinchildrenandadolescentsasystemicreviewandmetaanalysis AT ipenuelascalvo efficacyandtolerabilityofziprasidoneuseinchildrenandadolescentsasystemicreviewandmetaanalysis |